# Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

> **NCT03401346** · PHASE1 · COMPLETED · sponsor: **Impel Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Migraine Headache

## Interventions

- **COMBINATION_PRODUCT:** INP104
- **DRUG:** Dihydroergotamine Mesylate (DHE)
- **COMBINATION_PRODUCT:** Migranal Nasal Spray

## Key facts

- **NCT ID:** NCT03401346
- **Lead sponsor:** Impel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-19
- **Primary completion:** 2017-12-01
- **Final completion:** 2017-12-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401346, "Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03401346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*